SEO URLwww.firestrike.ai/deals/novartis-india-chryscapital-acquisition-2026
acquisitionAnnounced · Feb 19, 2026Chemical Manufacturing (325)Source · CredibleArticle · Factual
ChrysCapital acquires Novartis India
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Novartis India
BSE:500672 · Basel, Basel-City
Acquirer
ChrysCapital
Financial Stake
Status
Pending
ChrysCapital agreed to acquire Novartis India. Reported deal value: Undisclosed. Status: Pending. Sector: Not specified. Target headquarters context: Basel, Basel-City, Switzerland.
This page summarizes publicly available information about the transaction as of 2026-02-19. Figures and status may change as filings and press coverage update.
Chryscapital Fund X , a fund managed by ChrysCapital Advisors LLP and Two Infinity Partners entered into the Agreement to acquire to acquire 14.23% stake in Novartis India Limited from Novartis AG for INR 2.5 billion on February 19, 2026
Deal timeline
Announced
Feb 19, 2026 · in.marketscreener.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Chemical Manufacturing (325). Figures and status may change as sources update.
Sources: in.marketscreener.com · Primary article · FireStrike proprietary index